News
How Obama's FDA Directive Should Benefit Biopharma - Seeking Alpha
< strong > By < a href='http://seekingalpha.com/author/Scott-Matusow' > Scott Matusow < /a > : < /strong > < p > In October 2011, President Obama issued a directive to The FDA which in part, instructed it to get orphan designated drugs approved faster, with less stringency. I remarked in a < a
New Pharmaceutical Patent Reports from DrugPatentWatch.com | PRLog
New Pharmaceutical Patent Reports from DrugPatentWatch.com. New pharmaceutical patent intelligence reports profile patent challenges, orphan drugs, and leading inventors - PR11777011
Dove Medical Press Announces Dr Lise Aagaard as the Editor-in-Chief of Orphan Drugs: Research and
Dr Lise Aagaard has been appointed Editor-in-Chief of the new open access journal Orphan Drugs: Research and Reviews, published by Dove Medical Press
BioAlliance Pharma presents orphan drug survival results at international liver cancer congress |
BioAlliance Pharma SA announces oral communication of the phase 2 clinical trial results of its orphan product Livatag at the annual congress of ILCA (International Liver Cancer Association). Prof Philippe Merle, Professor of hepatology at the Hos...
Global Healthcare on the Ground: NIH Aims to Help Treat 200 Rare Diseases - Pharmaceutical
NIH leads new international consortium to develop a diagnostic tool for most known rare diseases by the year 2020.
Provectus Pharmaceuticals Inc. Receives Orphan Drug Designation from FDA for the Treatment of Liver
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTC BB:PVCT.ob - News), a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for Rose Bengal, the active ingredient in its
XOMA Antibody Receives Orphan Drug Designation from the FDA and EMA - - BioPharm International
The US Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta manufactured by XOMA, Ltd. (Berkley, CA), an orphan drug for the treatment of Behcet's disease.
Frost & Sullivan: Orphan Drugs to Create Paradigm Shift in the Pharmaceutical Industry! - News
PR NewswireLONDON, April 6, 2010LONDON, April 6, 2010 /PRNewswire/ -- The economic recovery process has proved difficult for the pharmaceutical industry. Factors like patent expiry, dry pipeline, and strict approval guidelines have slowed down the at
Frost & Sullivan: Orphan Drugs to Create Paradigm Shift in the Pharmaceutical Industry!
The economic recovery process has proved difficult for the pharmaceutical industry. Factors like patent expiry, dry pipeline, and strict approval guidelines, have slowed down the attractive drug discovery and industry growth. Coupled with an investment risk in new therapy or molecules, this creates
Orphan Drug Market Catches Pharma's Eye - Yahoo! Finance
To fortify itself against an uncertain future, Big Pharma will look to a class of drugs it has mostly ignored, says a new report from
Refine by Content Type:
Refine by Source:
- pharmtech.findpharma.com (23)
- www.biospace.com (18)
- www.thelancet.com (15)
- www.prlog.org (13)
- seekingalpha.com (10)
- www.dddmag.com (10)
- biopharminternational.findpharma.com (4)
- download.thelancet.com (4)
- investors.aastrom.com (4)
- www.pharmaceutical-business-review.com (4)
- www.pharmaasia.com (3)
- www.genengnews.com (3)
